NGM120 for Colorectal Cancer with Cancer Cachexia
This study is evaluating NGM120, a potential new treatment for cancer cachexia (severe weight loss and muscle wasting) in people with colorectal cancer. You might be eligible if you have an active diagnosis of colorectal cancer and meet specific criteria for cachexia, including recent weight loss. The study will compare NGM120 given every 4 weeks or every 8 weeks to a placebo (an inactive substance) to see how it affects body weight over 12 weeks. Researchers will also closely monitor any side effects for up to 44 weeks. The goal is to understand if NGM120 can help people with colorectal cancer who are experiencing cachexia.
- Study design
- This is a randomized, double-blind, placebo-controlled study involving about 136 participants. This means participants will be randomly assigned to receive NGM120 or a placebo, and neither you nor your doctors will know which treatment you are receiving.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will monitor treatment-emergent adverse events (side effects) for 44 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
At a glance
Conditions
Where it's being run
28 sites across 11 statesStudy leadership
- NGM Study Director · STUDY_DIRECTOR · NGM Biopharmaceuticals, Inc
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from baseline in body weight at Week 1212 Weeks
To evaluate the effect of NGM120 compared to placebo on body weight.
- Treatment-emergent adverse events (TEAEs) characterized by type, frequency, severity, timing, seriousness, and relationship to study drug44 Weeks
To evaluate safety and tolerability of NGM120